Literature DB >> 9780093

Comparison of glaucomatous progression between untreated patients with normal-tension glaucoma and patients with therapeutically reduced intraocular pressures. Collaborative Normal-Tension Glaucoma Study Group.

.   

Abstract

PURPOSE: To determine if intraocular pressure plays a part in the pathogenic process of normal-tension glaucoma.
METHODS: One eye of each eligible subject was randomized either to be untreated as a control or to have intraocular pressure lowered by 30% from baseline. Eyes were randomized if they met criteria for diagnosis of normal-tension glaucoma and showed documented progression or high-risk field defects that threatened fixation or the appearance of a new disk hemorrhage. The clinical course (visual field and optic disk) of the group with lowered intraocular pressure was compared with the clinical course when intraocular pressure remained at its spontaneous untreated level.
RESULTS: One hundred-forty eyes of 140 patients were used in this study. Sixty-one were in the treatment group, and 79 were untreated controls. Twenty-eight (35%) of the control eyes and 7 (12%) of the treated eyes reached end points (specifically defined criteria of glaucomatous optic disk progression or visual field loss). An overall survival analysis showed a statistically significant difference between the two groups (P < .0001). The mean survival time +/-SD of the treated group was 2,688 +/- 123 days and for the control group, 1,695 +/- 143 days. Of 34 cataracts developed during the study, 11 (14%) occurred in the control group and 23 (38%) in the treated group (P = .0075), with the highest incidence in those whose treatment included filtration surgery.
CONCLUSIONS: Intraocular pressure is part of the pathogenic process in normal-tension glaucoma. Therapy that is effective in lowering intraocular pressure and free of adverse effects would be expected to be beneficial in patients who are at risk of disease progression.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9780093     DOI: 10.1016/s0002-9394(98)00223-2

Source DB:  PubMed          Journal:  Am J Ophthalmol        ISSN: 0002-9394            Impact factor:   5.258


  413 in total

1.  Towards better treatment of glaucoma.

Authors:  P T Khaw; M F Cordeiro; M F Cordiero
Journal:  BMJ       Date:  2000-06-17

Review 2.  A hypothesis to explain ganglion cell death caused by vascular insults at the optic nerve head: possible implication for the treatment of glaucoma.

Authors:  N N Osborne; J Melena; G Chidlow; J P Wood
Journal:  Br J Ophthalmol       Date:  2001-10       Impact factor: 4.638

3.  Pathways for ATP release by bovine ciliary epithelial cells, the initial step in purinergic regulation of aqueous humor inflow.

Authors:  Ang Li; Chi Ting Leung; Kim Peterson-Yantorno; Claire H Mitchell; Mortimer M Civan
Journal:  Am J Physiol Cell Physiol       Date:  2010-10-06       Impact factor: 4.249

4.  Spatial pattern of glaucomatous visual field loss obtained with regionally condensed stimulus arrangements.

Authors:  Ulrich Schiefer; Eleni Papageorgiou; Pamela A Sample; John P Pascual; Bettina Selig; Elke Krapp; Jens Paetzold
Journal:  Invest Ophthalmol Vis Sci       Date:  2010-06-10       Impact factor: 4.799

5.  The negative correlation between age and intraocular pressures measured nyctohemerally in elderly normal-tension glaucoma patients.

Authors:  Koji Okada; Yuichi Tsumamoto; Makiko Yamasaki; Michiya Takamatsu; Hiromu K Mishima
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2002-12-17       Impact factor: 3.117

6.  Common actions of adenosine receptor agonists in modulating human trabecular meshwork cell transport.

Authors:  J C Fleischhauer; C H Mitchell; W D Stamer; M O Karl; K Peterson-Yantorno; M M Civan
Journal:  J Membr Biol       Date:  2003-05-15       Impact factor: 1.843

7.  A comparison of the fixed combination of latanoprost and timolol with the unfixed combination of brimonidine and timolol in patients with elevated intraocular pressure. A six month, evaluator masked, multicentre study in Europe.

Authors:  J García-Sánchez; J-F Rouland; D Spiegel; B Pajic; I Cunliffe; C Traverso; J Landry
Journal:  Br J Ophthalmol       Date:  2004-07       Impact factor: 4.638

Review 8.  Basis of chloride transport in ciliary epithelium.

Authors:  C W Do; M M Civan
Journal:  J Membr Biol       Date:  2004-07-01       Impact factor: 1.843

9.  Subconjunctival bevacizumab as an adjuvant in first-time filtration surgery for patients with primary glaucomas.

Authors:  Luis Gustavo Biteli; Tiago Santos Prata
Journal:  Int Ophthalmol       Date:  2013-02-07       Impact factor: 2.031

10.  Disc Hemorrhages Are Associated With the Presence and Progression of Glaucomatous Central Visual Field Defects.

Authors:  Aakriti G Shukla; Portia E Sirinek; C Gustavo De Moraes; Dana M Blumberg; George A Cioffi; Alon Skaat; Christopher A Girkin; Robert N Weinreb; Linda M Zangwill; Donald C Hood; Jeffrey M Liebmann
Journal:  J Glaucoma       Date:  2020-06       Impact factor: 2.503

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.